Skip To Main Content
Kathleen E Corey on Muck Rack

Kathleen E Corey

As seen in: Color Research & Application, Wiley, Frontline Gastroenterology, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Cell Metabolism, Cell Press, Gastroenterology, Clinical Gastroenterology and Hepatology, International Journal of Cardiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kathleen E

Contact Kathleen E, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bariatric Surgery as a Strategy for Improving Outcomes in Nonalcoholic Steatohepatitis

|
By Kathleen E Corey, Zoe Nicole Memel
| JAMA: Journal of the American Medical Association Verified
Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome, is the leading cause of liver disease worldwide. Nonalcoholic steatohepatitis (NASH) represents the progressive form of NAFLD, in which steatosis is accompanied by inflammation and fibrosis that can lead to cirrhosis.
Open in Who Shared Issue with article?

ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD

|
By Kathleen E Corey, Rebecca Pitts, Novartis Institutes, Michelle Lai
| Journal Of Hepatology EU Verified
Highlights • Aptamer-based profiling platform used to find proteins that non-invasively identify significant fibrosis in 316 adults with NAFLD. • An 8-protein panel can distinguish NAFL/NASH fibrosis stage 0-1 from fibrosis stage 2-4 with an AUROC of 0.87-0.89. • The ADAMTSL2 protein alone can distinguish NAFL/NASH fibrosis stage 0-1 from fibrosis stage 2-4 with an AUROC of 0.83-0.86.
Open in Who Shared Issue with article?

Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease

|
By Byrne C.D, Thomas Mayrhofer, Kathleen E Corey, Nandini M. Meyersohn
| Clinical Gastroenterology and Hepatology Verified
Background & Aims Hepatic steatosis has been associated with increased risk of major adverse cardiovascular events (MACE) but it is not clear whether steatosis is independently associated with risk of MACE. We investigated whether steatosis is associated with risk of MACE independently of the presence and extent of baseline coronary artery disease, assessed by comprehensive contrast-enhanced computed tomography angiography (CTA).
Open in Who Shared Issue with article?
See all 13 licensed articles (14 Total)